Related protein group with differential expression in early pancreatic cancer model and application thereof

Abstract

In the invention, differential expression of proteins in tissues of normal pancreas and the pancreas of a rat with pancreatic intraepithelial neoplasia and early pancreatic cancer can be respectively dynamically detected by establishing a 7,12-dimethyl benzophenanthrene (DMBA)-induced rat pancreatic intraepithelial neoplasia and pancreatic cancer model and applying the DIGE (difference gel electrophoresis) protein analysis technology, bioinformatics software is utilized for screening out the proteins which synchronously significantly vary with expression of cancerization degree of the pancreatic cancer, and the mass spectrometry technology is further utilized for performing identification so as to determine the specific proteins with the differential expression during the occurrence of the early pancreatic cancer. The invention discloses a related protein group with the differential expression in the pancreas tissues in an early pancreatic cancer model, the related proteins have strong specificity, and the related proteins can be utilized as protein markers for early diagnosis of the pancreatic cancer, thereby providing an effective method for clinical early diagnosis of the pancreatic cancer. A PMF (peptide mass fingerprinting) map of differential protein points can be searched in a database of National Center for Biotechnology Information (NCBI) by utilizing Mascot software.

Description

technical field [0001] The invention relates to differential proteomics technology, more specifically, relates to a group of related proteins differentially expressed in early pancreatic cancer models and applications thereof. Background technique [0002] Pancreatic cancer has biological characteristics such as insidious onset, early metastasis, and high degree of malignancy, which makes early diagnosis of pancreatic cancer difficult and the clinical treatment effect is poor. Establishing ideal tumor markers for early diagnosis of pancreatic cancer, through screening normal or high-risk groups, and early detection of suspicious cases is of great significance for improving the clinical early diagnosis level and treatment effect of pancreatic cancer. [0003] Currently commonly used diagnostic methods have a very low diagnostic rate for early pancreatic cancer. The current methods mainly include (1) Imaging and endoscopy: computed tomography (CT) is useful in judging the stag...

AI Technical Summary

Problems solved by technology

[0004] (2) Serum tumor markers: Serum tumor markers have a long history of development. At present, CA19-9, CA50, CA242, Span-1, MIC-1, Dupan-2, etc. are commonly used in clinical practice. Sensitivity and specificity are not very satisfactory, and the diagnostic effect on early pancreatic cancer is even more unsatisfactory

The specific mechanism of DMBA-induced pancreatic cancer is not well understood at present, but studies have found that DMBA-induced PanIN and pancreatic cancer have K-ras gene mutations as high as 90%, and the expression levels of smad 4, cyclin Dl and p53 are similar to those of human pancreas. cancer similar

Images